Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: Survey on coverage rate among elderly and chronic patients

Martinelli, Domenico; Tafuri, Silvio; Caputi, G; Fortunato, Francesca; Reggio, Paolo; Germinario, Cinzia Annatea; Prato, Rosa

doi:10.1016/j.ajic.2009.09.019

Cited by 15 publications

(15 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, that rate among adults aged ≥ 75 years reached 12% in 2007 and 41% in 2008, attributed to the implementation of PPV23-free policy in this population, but thereafter dropped to 29.5% with unclear reasons. In contrast, Martinelli et al estimated the PPV23 coverage rate among individuals ≥ 65 years during the years of 2002-2007 was 46.6% in Italy 14 . While Zhou et al estimated the PPV23 coverage rate among adults ≥ 65 years in Quebec province of Canada increased from 48% in 2006 to 57% in 2014 15 .…”

Section: Introductionmentioning

confidence: 90%

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly

Huang

Wang

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

To evaluate the safety and immunogenicity of a newly 23-valent pneumococcal polysaccharide vaccine (PPV23), a phase Ⅲ clinical trial was conducted in population aged ≥ 2 years. We conducted a randomized, double-blinded, active controlled trial, in which 1760 participants were randomly assigned in a 1:1 ratio to receive one dose of either the test vaccine or the control commercial vaccine. The surveillance period was 28 days. The 2-fold increase rate of anti-pneumococcal for 23 serotypes varied from 49.71% to 90.96% in the treatment group and from 44.52% to 88.24% in the control group. According to -10% non-inferiority margin and 95% confidence intervals of rate difference, all the 23 serotypes of the treatment group were non-inferiority to the control group. The 2-fold increase rate of anti-pneumococcal antibody were significantly higher in the treatment group for 11 serotypes including 1, 2, 3, 4, 10A, 11A, 14, 18C, 20, 22F, and 23F. Serious adverse events occurred in 2 in 879 (0.23%) participants in the treatment group and 2 in 880 (0.23%) participants in the control group, and all the adverse events were unrelated to the vaccination. The overall adverse reaction frequency showed no difference between the treatment (51.19%) and control group (47.95%), and most adverse reactions were mild or moderate in intensity. The newly PPV23 is immunologically non-inferior to the control commercial vaccine and well tolerated in healthy Chinese population aged ≥ 2 years. Trial registration: ClinicalTrial.gov identifier: NCT02451969.

show abstract

Section: Introductionmentioning

confidence: 90%

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly

Huang

Wang

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…The low VrPPV23 among older adults observed in this study is similar to previous studies. [ 3 , 16 , 17 ] Although the PPV23 has been globally recommended for many years, a large disparity in VrPPV23 exists among various countries. [ 16 , 18 – 22 ] In addition to the low VrPPV23 (20.7%) in older adults, we observed that those strongly recommended to receive the PPV23 were actually less likely to receive the vaccine.…”

Section: Discussionmentioning

confidence: 99%

“…The 23-valent pneumococcal polysaccharide vaccine (PPV23) prevents invasive pneumococcal diseases and reduces mortality among older adults. [ 1 – 3 ] Older adults are thus advised to receive the PPV23 according to the recommendations of the US Advisory Committees on Immunization Practices. [ 4 , 5 ] In particular, lower respiratory tract infections, with Streptococcus pneumoniae as one of the leading pathogens, is a major cause of mortality among patients with chronic obstructive pulmonary disease (COPD).…”

Section: Introductionmentioning

confidence: 99%

Vaccination coverage and associated factors for receipt of the 23-valent pneumococcal polysaccharide vaccine in Taiwan

Chen

2018

Medicine

View full text Add to dashboard Cite

Older adults, particularly those with chronic obstructive pulmonary disease, are advised to receive 23-valent pneumococcal polysaccharide vaccine (PPV23). However, the PPV23 vaccination rate in Taiwan and the determinants of receipt remain unclear.We analyzed the data of 1475 community-dwelling older adults aged ≥75 years who participated in the Healthy Aging Longitudinal Study in Taiwan. Each participant received assessments of PPV23 status, sociodemographic factors (age, sex, education level, marital status, living alone, and occupation), and health-related factors (chronic diseases, smoking status, alcohol intake, physical activities, cognitive status, and physical performance). PPV23 rate was defined as the number of participants who reported receiving free PPV23 divided by the total number of candidates for free PPV23. Multinomial logistic regression analysis was applied to investigate the sociodemographic and health-related determinants of PPV23 status.A PPV23 vaccination rate of 20.7% (305/1475) was observed. Participants who were female, current smokers, and had a low peak expiratory flow were associated with PPV23 nonreceipt (all P <.05). Of the participants who had a low peak expiratory flow, low education status, and physical inactivity were associated with PPV23 nonreceipt (all P <.05).The PPV23 vaccination rate among adults aged ≥75 years was low. Older adults who were women, current smokers, or who had a low PEF were less likely to receive the PPV23. These findings support continual efforts to improve the PPV23 coverage rate in vulnerable populations.

show abstract

“…14 Estimates of PPSV23 coverages among elderly populations in Western European countries vary between 20% and 69% in distinct settings (probably reflecting national recommendations and program funding). 5,[14][15][16][17][18][19][20] Considering that the use of the PCV13 in adults has only been approved recently, there is no published data about PCV13 uptakes. We note that, at present, recommendations for pneumococcal vaccination in adults are not homogeneous in distinct countries, scientific societies and/or clinical guidelines.…”

Section: Ppsv23 Vaccinated Within Previous 5 Yrs N (%)mentioning

confidence: 99%

Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia

Vila-Córcoles

Ochoa-Gondar

Diego

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

There is scarce data about pneumococcal vaccination coverages among adults in recent years. We investigated current pneumococcal vaccination coverages in Catalonia, Spain, with a cross-sectional population-based study including 2,033,465 individuals aged 50 y or older assigned to the Catalonian Health Institute at 01/01/2015 (date of survey). A previously validated institutional research clinical Database was used to classify study subjects by their vaccination status for both 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13), to identify comorbidities and underlying conditions, and establish the risk stratum of each individual: High risk stratum: functional or anatomic asplenia, cochlear implants, CSF leaks, or immunocompromising conditions; medium risk stratum: immunocompetent persons with history of chronic cardiac or respiratory disease, liver disease, diabetes mellitus, alcoholism and/or smoking; low risk stratum: persons without high or medium risk conditions. Of the total 2,033,465 study population, an amount of 789,098 (38.8%) had received PPVS23, whereas 5031 (0.2%) had received PCV13. PPSV23 coverages increased largely with increasing age: 4.8% in 50-59 y vs 35.5% in 60-69 y vs 71.9% in 70-79 y vs 79.5% in 80 y or older; p < 0.001). PCV13 coverages also increased with age, although they were very low in all age groups. PPSV23 coverages were 59.2% in high risk stratum, 48.3% in medium risk stratum and 28.1% in low risk stratum (p < 0.001). For the PCV13, uptakes were 1.2%, 0.3% and 0.1% in high, medium and low stratum, respectively (p < 0.001). In conclusion, pneumococcal vaccination coverages in Catalonian adults are not optimal, being especially small for the PCV13 (even in high-risk subjects).

show abstract

Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: Survey on coverage rate among elderly and chronic patients

Cited by 15 publications

References 14 publications

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly

Vaccination coverage and associated factors for receipt of the 23-valent pneumococcal polysaccharide vaccine in Taiwan

Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia

Contact Info

Product

Resources

About